IP Library Granted Patent US 8,383,340
Granted Patent B2
US 8,383,340 · App. 12/520,172 · Granted Feb 26, 2013

Method for purifying RNA on a preparative scale by means of HPLC

Inventors: Thomas Ketterer (Tübingen, DE); Florian Von Der Mulbe (Stuttgart, DE); Ladislaus Reidel (Rottenburg, DE); Thorsten Mutzke (Reutlingen, DE)
Assignee: Curevac GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,340
App. No.
12/520,172
Granted
Feb 26, 2013
Kind
B2
Abstract

The application describes a method for the preparative purification of RNA, which method is distinguished in that the RNA is purified by means of HPLC using a porous reversed phase as the stationary phase. The use of the porous reversed phase in this HPLC method is also described.

Claims (26)

1. A method for purifying RNA on a preparative scale, wherein the RNA is purified by HPLC or low or normal pressure liquid chromatography using a porous reversed phase as stationary phase and a mobile phase, wherein the porous reversed phase is a porous non-alkylated polystyrenedivinylbenzene.

2. A method according to claim 1 , wherein the RNA is selected from among tRNA, rRNA, mRNA or whole-cell RNA, and RNA variants.

3. A method according to claim 1 , wherein the RNA has a size of up to about 15000 nucleotides or base pairs.

4. A method according to claim 1 , wherein the RNA has a size of up to 100 to 10000 nucleotides or base pairs.

5. A method according to claim 1 , wherein the porous reversed phase has a particle size of 8 μm to 50 μm.

6. A method according to claim 1 , wherein the reversed phase has a pore size of 1000 Å to 5000 Å.

7. A method according to claim 1 , wherein the reversed phase has a pore size of 1000 Å to 4000 Å.

8. A method according to claim 1 , wherein the porous reversed phase is formed by beads or occurs as a polymerized block.

9. A method according to claim 1 , wherein the HPLC column has a length of more than 5 cm up to 100 cm and a diameter of more than 4 mm up to 1 m.

10. A method according to claim 1 , wherein HPLC purification is performed as an ion pair method, an ion with positive charge being added to the mobile phase as counterion to the negatively charged RNA, or by size exclusion chromatography, gel filtration, affinity chromatography, hydrophobic interaction chromatography or ion pair chromatography.

11. A method according to claim 1 , wherein a mixture of an aqueous solvent and an organic solvent is used for HPLC purification in the mobile phase for the purpose of elution.

12. A method according to claim 11 , wherein the aqueous solvent is a buffer.

13. A method according to claim 12 , wherein the buffer is selected from the group consisting of triethylammonium acetate, trifluoroacetic acid, acetic acid, formic acid, acetate buffer, phosphate buffer, tetrabutylammonium bisulfate, tetrabutylammonium bromide and tetrabutylammonium chloride.

14. A method according to claim 13 , wherein the triethylammonium acetate buffer is a 0.1 M triethylammonium acetate buffer.

15. A method according to claim 11 , wherein the organic solvent is acetonitrile, methanol, ethanol, 1-propanol, 2-propanol and acetone or a mixture thereof.

16. A method according to claim 15 , wherein the organic solvent is acetonitrile.

17. A method according to claim 11 , wherein the mixture of an aqueous solvent and an organic solvent comprises 0.1 M triethylammonium acetate and acetonitrile.

18. A method according to claim 11 , wherein the mixture of an aqueous solvent and an organic solvent consists of 5.0 vol. % to 25.0 vol. % organic solvent the aqueous solvent.

19. A method according to claim 18 , wherein the mixture of an aqueous solvent and an organic solvent consists of 7.5 vol. % to 17.5 vol. % organic solvent the aqueous solvent.

20. A method according to claim 11 , wherein the elution proceeds isocratically.

21. A method according to claim 1 , wherein a gradient separation proceeds.

22. A method according to claim 21 , wherein, in the event of gradient separation, the proportion of organic solvent is increased by at least 10% relative to the initial vol. % in the mobile phase.

23. A method according to claim 22 , wherein the proportion of organic solvent in the mobile phase in the course of HPLC separation amounts to from 3 to 9 vol. %.

24. A method according to claim 22 , wherein the proportion of organic solvent in the mobile phase is increased in the course of HPLC separation from 3 to 9 vol. %, in each case relative to the mobile phase.

25. A method according to claim 24 , wherein the proportion of organic solvent in the mobile phase is increased in the course of HPLC separation from 6.5 to 8.5 vol. %, in each case relative to the mobile phase.

26. A method according to claim 1 , wherein the RNA is purified by HPLC using a porous reversed phase as stationary phase, wherein the porous reversed phase is a porous non-alkylated polystyrenedivinylbenzene.

Assignments (4)
CHANGE OF NAME Recorded Feb 18, 2023
From: CUREVAC REAL ESTATE GMBH
To: CUREVAC MANUFACTURING GMBH
Reel/Frame 062800/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2020
From: CUREVAC AG
To: CUREVAC REAL ESTATE GMBH
Reel/Frame 051487/0680 →
CHANGE OF NAME Recorded Nov 16, 2015
From: CUREVAC GMBH
To: CUREVAC AG
Reel/Frame 037115/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2009
From: KETTERER, THOMAS; VON DER MULBE, FLORIAN; REIDEL, LADISLAUS; MUTZKE, THORSTEN
To: CUREVAC GMBH
Reel/Frame 023388/0888 →
Priority Claims (1)
DE 10 2006 061 015 · Dec 22, 2006 · national
Continuity (1)
Related Publication 20100048883A1 · Feb 25, 2010